PURCHASE AGREEMENT IMMUNOGEN, INC. Purchase AgreementPurchase Agreement • June 20th, 2016 • Immunogen Inc • Pharmaceutical preparations • New York
ImmunoGen, Inc., a Massachusetts corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representative (the “Representative”), $100,000,000 principal amount of its 4.50% Convertible Senior Notes due 2021 (the “Underwritten Securities”) and, at the option of the Initial Purchasers, up to an additional $15,000,000 principal amount of its 4.50% Convertible Senior Notes due 2021 (the “Option Securities”) if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such 4.50% Convertible Senior Notes due 2021 granted to the Initial Purchasers in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into shares (the “Underlying Securities”) of common stock of the Company, par value $0.01 per share (the “Common Stock”). The Securities wi
ImmunoGen, Inc. (Company) Wilmington Trust, National Association (Trustee) 4.50% Convertible Senior Notes due 2021 INDENTURE Dated as of June 20, 2016Immunogen Inc • June 20th, 2016 • Pharmaceutical preparations • New York
INDENTURE, dated as of June 20, 2016, between ImmunoGen, Inc., a Massachusetts corporation, as issuer (the “Company”), and Wilmington Trust, National Association, as trustee, conversion agent, registrar and paying agent (in such capacities, the “Trustee”, “Conversion Agent”, “Registrar” and “Paying Agent”, respectively).
